Twelve‐Month Outcome of Nasolabial Fold Correction by a Novel Non‐1,4‐Butanediol Diglycidyl Ether, Click‐Crosslinked, Long‐Chain Hyaluronic Acid Product
Journal of Cosmetic Dermatology · 2026-04 · 25 (4)
DOI: 10.1111/jocd.70840 ↗Kurz gefasst
Klinische Studie in der Zeitschrift Journal of Cosmetic Dermatology, online erschienen am 24.04.2026. Verfasst von Ari Safir und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Dermatology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel. Hauptthemen laut MEDLINE: Cosmetic Techniques, Cross-Linking Reagents, Dermal Fillers, Hyaluronic Acid. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Hallura Ltd.
Abstract (Originalsprache)
Background
Hyaluronic acid (HA) products used for nasolabial fold (NLF) correction are typically crosslinked with 1,4‐Butanediol diglycidyl ether (BDDE) and contain high HA concentrations and short HA chains. These characteristics may contribute to increased stiffness, enhanced immune reactivity, and less natural aesthetic outcomes. A novel HA material utilizing click‐chemistry for crosslinking to preserve long‐chain structure and afford low HA concentration and minimal modification was developed as a potential alternative.
Aim
The aim of this study was to evaluate the 12‐month safety and clinical performance of a non‐BDDE, click‐chemistry crosslinked, long‐chain HA compound (HLR‐2, Hallura) for NLF correction.
Methods
Two prospective, open‐label studies were conducted, one in Europe and the other in Israel. All subjects received HLR‐2 injections and were followed for 12 months. Efficacy was assessed by the Wrinkle Severity Rating Scale, Global Aesthetic Improvement Scale, and patient satisfaction measures. Safety was monitored through reporting of adverse events (AE) and documentation of injection site reactions (ISR).
Results
Sixty‐two subjects (29 Israeli and 33 European) were included. Responder rates at 6 months were 90.7% and 86.4%, respectively, with improvements sustained throughout 12 months. Satisfaction levels remained high (≥ 94% at all time points). ISRs were mild and transient, with no serious or delayed‐onset AEs, and favorable induction of collagen and elastin and enhanced tissue integration were documented.
Conclusion
HLR‐2 demonstrated high efficacy, high patient satisfaction, and a favorable safety profile over 12 months. The product's distinctive composition and clinical performance support its use for aesthetic indications, with potential for broader therapeutic applications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Dermatology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
- Faculty of Medical & Health Sciences, Tel Aviv University, Tel Aviv, Israel.
- Rosenpark Klinik, Darmstadt, Germany.
- Private Practice Dr. Hilton & Partner for Dermatology, Düsseldorf, Germany.
- Maria Skłodowska-Curie Medical Academy in Warsaw, Warsaw, Poland.
- Evimed, Warsaw, Poland.
ORCID-Profile: Ari Safir
Förderung
- Hallura Ltd
Zitieren
APA
Safir, A., Sattler, S., Da Mota, R., Kowalska-Olędzka, E., Kedar, D. J., Gronovich, Y., Lotan, A. M., Shneider, S., Meunier, S., & Artzi, O. (2026). Twelve‐Month Outcome of Nasolabial Fold Correction by a Novel Non‐1,4‐Butanediol Diglycidyl Ether, Click‐Crosslinked, Long‐Chain Hyaluronic Acid Product. Journal of Cosmetic Dermatology, 25(4). https://doi.org/10.1111/jocd.70840
Vancouver
Safir A, Sattler S, Da Mota R, Kowalska-Olędzka E, Kedar DJ, Gronovich Y, et al. Twelve‐Month Outcome of Nasolabial Fold Correction by a Novel Non‐1,4‐Butanediol Diglycidyl Ether, Click‐Crosslinked, Long‐Chain Hyaluronic Acid Product. Journal of Cosmetic Dermatology. 2026;25(4). doi:10.1111/jocd.70840
BibTeX
@article{Safir2026,
author = {Safir, Ari and Sattler, Sonja and Da Mota, Rodrigo and Kowalska-Olędzka, Elzbieta and Kedar, Daniel J and Gronovich, Yoav and Lotan, Adi Maisel and Shneider, Svetlana and Meunier, Stephane and Artzi, Ofir},
title = {Twelve‐Month Outcome of Nasolabial Fold Correction by a Novel Non‐1,4‐Butanediol Diglycidyl Ether, Click‐Crosslinked, Long‐Chain Hyaluronic Acid Product},
journal = {Journal of Cosmetic Dermatology},
year = {2026},
volume = {25},
number = {4},
doi = {10.1111/jocd.70840}
}
EUVIMED